Eikon Therapeutics $381 million IPO
We advised the representatives of the several underwriters on the IPO
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
AbelZeta sale of China rights to GPC3 CAR-T therapy to AstraZeneca
We advised AbelZeta on the transaction
Penumbra $14.5 billion sale to Boston Scientific
We are advising Penumbra on the transaction
Aktis Oncology $318 million IPO
This is the first biotech IPO of 2026
W. L. Gore & Associates acquisition of Conformal Medical
We are advising Gore on the transaction
GSK strategic collaboration with CAMP4 Therapeutics
We advised GSK on the transaction
Novo Nordisk proposed $9.1 billion acquisition of Metsera
We are advising Novo Nordisk on the transaction
GSK exclusive license agreement with Empirico
We advised GSK on the transaction
Turn Therapeutics direct listing
We advised Turn Therapeutics on its Nasdaq listing
Amulet Capital Partners sale of SSI Strategy to Clinigen
We are advising Amulet Capital Partners and SSI Strategy on the sale